Published in Am J Pathol on April 29, 2010
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med (2013) 1.11
GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res (2015) 0.99
Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer (2014) 0.99
GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. Respir Res (2011) 0.97
Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol (2012) 0.94
Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth Metastasis (2015) 0.91
Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1. Br J Cancer (2013) 0.87
Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy. Cancer Sci (2014) 0.86
Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol (2013) 0.85
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81
The relationship of serum macrophage inhibitory cytokine-1 levels with gray matter volumes in community-dwelling older individuals. PLoS One (2015) 0.77
Targeting macrophage anti-tumor activity to suppress melanoma progression. Oncotarget (2017) 0.75
A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT). Oncotarget (2017) 0.75
TGFbeta in Cancer. Cell (2008) 17.44
Melanoma biology and new targeted therapy. Nature (2007) 10.71
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res (2001) 6.73
MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med (2006) 4.60
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A (1997) 4.20
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev (2003) 3.46
Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res (2005) 3.30
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics (2008) 3.11
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev (2000) 2.43
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res (2008) 2.18
A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem (2001) 1.94
Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res (2006) 1.93
Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res (2006) 1.79
Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol (2008) 1.76
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res (2003) 1.71
Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer (2007) 1.70
Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res (2001) 1.64
Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res (2003) 1.58
Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem (2000) 1.58
Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res (2006) 1.56
Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res (2008) 1.56
PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A (2000) 1.55
PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res (2007) 1.52
Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res (2008) 1.51
Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol (2008) 1.49
Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol (2000) 1.46
Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res (2003) 1.45
MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol (1999) 1.44
Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther (2003) 1.41
A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell (2002) 1.32
Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res (2007) 1.31
Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res (2003) 1.31
Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis (2008) 1.27
Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res (2008) 1.18
GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res (2006) 1.16
Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. Cancer Res (2009) 0.99
The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res (2005) 0.98
Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells. Int J Cancer (2005) 0.91
Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase. Hypertens Res (2008) 0.84
A novel p53 transcriptional repressor element (p53TRE) and the asymmetrical contribution of two p53 binding sites modulate the response of the placental transforming growth factor-beta promoter to p53. J Biol Chem (2002) 0.80
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res (2008) 2.18
eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res (2011) 2.10
Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem (2004) 1.75
A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. Gene (2004) 1.64
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2009) 1.62
Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res (2005) 1.60
Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res (2003) 1.58
Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res (2006) 1.56
Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res (2010) 1.55
PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res (2007) 1.52
Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res (2008) 1.51
Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem (2006) 1.36
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res (2007) 1.31
Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res (2009) 1.22
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res (2008) 1.22
Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res (2008) 1.18
KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst (2010) 1.14
Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol (2004) 1.13
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett (2008) 1.12
Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway. Sci Signal (2009) 1.11
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology (2007) 1.09
New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol (2012) 1.08
Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J (2010) 1.07
Ptena and ptenb genes play distinct roles in zebrafish embryogenesis. Dev Dyn (2005) 1.00
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J Med Chem (2008) 0.99
Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol (2011) 0.98
Sequential binding of αVβ3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils. J Immunol (2010) 0.95
PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Mol Cancer Ther (2008) 0.94
Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res (2012) 0.94
Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev Res (Phila) (2010) 0.93
Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide. Stem Cells Dev (2010) 0.92
Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p. J Pharmacol Exp Ther (2014) 0.92
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2013) 0.91
Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res (2009) 0.90
The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89
Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle (2013) 0.88
Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer. Bioorg Med Chem Lett (2009) 0.86
Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther (2012) 0.86
Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res (2012) 0.85
Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol (2013) 0.85
Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res (2011) 0.85
Melanoma prevention using topical PBISe. Cancer Prev Res (Phila) (2011) 0.84
Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Mol Cancer Ther (2012) 0.82
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81
A nonradioactive plate-based assay for stimulators of nonspecific DNA nicking by HIV-1 integrase and other nucleases. Anal Biochem (2009) 0.81
Identification of tumor suppressive activity by irradiation microcell-mediated chromosome transfer and involvement of alpha B-crystallin in nasopharyngeal carcinoma. Int J Cancer (2008) 0.79
Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Mol Diagn Ther (2014) 0.78
Evaluation of a system to screen for stimulators of non-specific DNA nicking by HIV-1 integrase: application to a library of 50,000 compounds. Antivir Chem Chemother (2011) 0.78
Growth inhibitory effects of large subunit ribosomal proteins in melanoma. Pigment Cell Melanoma Res (2014) 0.77
Identification of steroid derivatives that function as potent antiandrogens. Int J Cancer (2005) 0.77
Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. Cancer Biol Ther (2011) 0.76
Identification of a novel lysosomal trafficking peptide using phage display biopanning coupled with endocytic selection pressure. Bioconjug Chem (2014) 0.76
Chemoprevention of melanoma. Adv Pharmacol (2012) 0.76
Steroid hormones drive cancer development. Cancer Biol Ther (2010) 0.76
Models of melanoma metastasis: using a transient siRNA-based protein inhibition strategy in mice to validate the functional relevance of pharmacological agents. Curr Protoc Pharmacol (2007) 0.76
In situ photoimmunotherapy: a new hope for cutaneous melanoma patients. Cancer Biol Ther (2010) 0.75